2.5000 +0.07 (2.88%)
After hours: 4:01PM EST
Previous Close | 2.6800 |
Open | 2.6200 |
Bid | 2.4300 x 900 |
Ask | 2.4600 x 1200 |
Day's Range | 2.4203 - 2.6700 |
52 Week Range | 0.4400 - 5.8500 |
Volume | 358,913 |
Avg. Volume | 3,755,567 |
Market Cap | 21.251M |
Beta (5Y Monthly) | 2.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCARTâ„¢, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at NobleCon17 - Noble Capital Markets' Seventeenth Annual Investor Conference on Tuesday, January 19, 2021 at 9:45 AM ET.
FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc.
FRAMINGHAM, MA / ACCESSWIRE / December 14, 2020 / Xenetic Biosciences, Inc.